Doctor Explains How the FDA Vote Changes BPC-157, TB-500, KPV & MOTS-c
Dr. Jones, DC — Doctor Explains How the FDA Vote Changes BPC-157, TB-500, KPV & MOTS-c
Channel: Dr. Jones, DC · Our label: Chiropractor / clinician creator · Source: youtube.com/watch?v=Bsmwwf1wk9Y
What this video covers
The excitement is running so high right now that vendors are already emailing their customers that the FDA approved BPC-157. I had a compounding pharmacist tell me that he’s literally getting these emails. An FDA advisory committee took all four of these compounds up and voted on every single one of them. So, the excitement isn’t coming from nowhere.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- The excitement is running so high right now that vendors are already emailing their customers that the FDA approved BPC-157.
- My clinic prescribes several of these compounds today.
- Somebody on that panel put FDA on the spot and asked them cold, hey, what makes peptides risky in the first place?
- Over the two full days, we got one answer, one general theory of peptide risk from the agency itself, and it isn’t even about the peptides.
- So, a yes vote, the outcome everybody was rooting for, still wouldn’t have meant FDA approved BPC-157.
- And the FDA said, filing the application to study something in humans, the formal permission to run a trial, it costs nothing.
Read next
- BPC-157 — compound page
- TB-500 — compound page
- MOTS-c — compound page
- KPV — compound page
- All videos from this channel
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.